Core Viewpoint - Kestra Medical Technologies, Ltd. has announced an upsized underwritten public offering of 6,000,000 common shares priced at $23.00 per share, aiming for gross proceeds of $138 million before expenses [1]. Company Overview - Kestra Medical Technologies, Ltd. is a commercial-stage company focused on wearable medical devices and digital healthcare, specifically targeting improvements in patient outcomes for cardiovascular diseases through innovative monitoring and therapeutic technologies [6]. Offering Details - The offering is expected to close on December 4, 2025, pending customary closing conditions [1]. - Underwriters have a 30-day option to purchase an additional 900,000 common shares at the public offering price [1]. - The offering is being managed by BofA Securities, Piper Sandler, J.P. Morgan, Goldman Sachs & Co. LLC, and Wells Fargo Securities as bookrunners [2].

Core Points - Kestra Medical Technologies, Ltd. will be added to the Russell 3000® Index, with automatic inclusion in the Russell 2000® Index, effective after the U.S. market close on June 27, 2025 [1] - The Russell indexes capture the 4,000 largest U.S. stocks as of April 30, ranked by total market capitalization, and are widely used by investment managers and institutional investors for index funds and benchmarks [2] - The inclusion in the Russell indexes is seen as a significant milestone for Kestra following its initial public offering in March 2025, reflecting the company's commitment to expanding its market presence and creating long-term shareholder value [3] Company Overview - Kestra Medical Technologies, Ltd. is a commercial-stage wearable medical device and digital healthcare company focused on improving patient outcomes in cardiovascular disease through innovative monitoring and therapeutic intervention technologies [4]